| David Charles Brooks, PHARMD | |
|
3107 Lurleen B Wallace Blvd, Northport, AL 35476 | |
| (205) 333-9343 | |
| (205) 333-1544 |
| Full Name | David Charles Brooks |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 3107 Lurleen B Wallace Blvd, Northport, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578174504 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PS55946 (Florida) | Secondary |
| 183500000X | Pharmacist | 19678 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Charles Brooks, PHARMD 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Ph: (205) 333-9343 | David Charles Brooks, PHARMD 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Ph: (205) 333-9343 |
News Archive
Since the 1980s, federal and local governments have increasingly used public money to hire private firms to house and manage people who are incarcerated.
In adults with persistent asthma, elevated blood eosinophil levels may be able to predict which individuals are at increased risk for exacerbations, according to a new study presented at the 2014 American Thoracic Society International Conference.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to identify disease processes at an early stage and to track responses to treatment.
Synthon has announced that its subsidiary Synthon Pharmaceuticals, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for tadalafil tablets, 20 mg on April 13, 2012. Synthon's product is a generic and bioequivalent version of Eli Lilly & Co and United Therapeutics' Adcirca® tablets, which are indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
› Verified 8 days ago
Daniel Lee Webber, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Phone: 205-333-9343 Fax: 205-333-1544 | |
Dr. Jessica Jo Salvatore, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5710 Mcfarland Blvd, Northport, AL 35476 Phone: 205-333-7873 | |
Nicholas Matthew Witucki, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Phone: 205-333-9343 | |
Casey Rasinen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Phone: 205-333-9343 | |
Dr. Zachary Grant Hunt, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3107 Lurleen B Wallace Blvd, Northport, AL 35476 Phone: 205-333-9343 | |
Jann Sides, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 Mcfarland Blvd, Northport, AL 35476 Phone: 205-339-0155 Fax: 205-339-1316 | |
Dr. Robert Meaders Bragg, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2300 Mcfarland Blvd, Northport, AL 35476 Phone: 205-339-2700 |